Methotrexat Ebewe (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, preventing the formation of tetrahydrofolate, a key cofactor for synthesising purine nucleotides and thymidylate. Without these building blocks, DNA, RNA and protein synthesis are reduced, which limits the growth of rapidly dividing cells such as immune cells in autoimmune disease and cancer cells in malignancies.

The specific dose of Methotrexat Ebewe is determined by the prescribing clinician based on the individual patient's diagnosis, disease severity, renal and hepatic function, and other clinical factors. Dosage regimens vary widely across indications and are not standardized in product literature.

Methotrexat Ebewe is classified as pregnancy category X, meaning it is contraindicated in pregnancy because it can cause fetal malformations and loss. It is also not recommended while breastfeeding, as it may be excreted in milk and harm the infant. Effective contraception is required for women of child‑bearing potential.

To request Methotrexat Ebewe, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if required) and any necessary import documentation.

Methotrexat Ebewe, like other methotrexate products, is a folate antagonist and shares a similar mechanism with drugs such as pemetrexed. Compared with newer targeted agents, methotrexate has a broader indication profile but may require more intensive monitoring for toxicity. Choice of therapy depends on disease, patient factors and clinician judgment.

Methotrexat Ebewe should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original container, protect it from moisture and direct light, and avoid freezing. Follow any additional handling instructions provided with the shipment to maintain product integrity.

Methotrexat Ebewe is supplied as a sterile injectable solution and can be given by intra‑arterial, intramuscular or intrathecal injection, depending on the clinical indication and prescribing physician’s plan. Administration techniques follow standard aseptic procedures and dosing schedules established by the treating clinician.

The most serious adverse events include severe bone marrow suppression leading to pancytopenia, hepatotoxicity that can progress to fibrosis or cirrhosis, pulmonary fibrosis, and acute renal failure. Patients should be monitored regularly for blood counts, liver and kidney function, and any signs of infection or respiratory difficulty.

Methotrexat Ebewe is contraindicated in patients with known hypersensitivity to methotrexate, severe hepatic impairment, active infections, and in pregnant women. Caution is also advised for individuals with pre‑existing kidney disease, uncontrolled diabetes, or those taking interacting medications that could increase toxicity.